Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.
作者： Marc Berns , Daniel W. Hommes
DOI: 10.1517/13543784.2016.1126247
关键词: Oncology 、 Crohn's disease 、 Surgical interventions 、 Biosimilar 、 Anti tnf α 、 Remission induction 、 Golimumab 、 Internal medicine 、 Disease 、 Medicine 、 Pharmacology
摘要: ABSTRACTIntroduction: Anti-TNF-α therapy is a novel approach that has transformed the way moderate-to-severe Crohn’s disease (CD) treated and significantly improved clinical outcomes of patients with enhanced remission induction maintenance efficacies. As result, anti-TNF-α agents have become primary cost driver in treatment CD, as frequency hospitalizations surgical interventions been drastically reduced.Areas Covered: In review, authors cover current treatments for CD including efficacy, mechanisms action, pharmacokinetics safety. addition, discuss future currently development pipeline biosimilars, golimumab, oral AVX-470, TNF-α-kinoid vaccine, non-biologic HMPL-004.Expert opinion: While new therapeutics are like anti-integrin anti-interleukin therapeutics, remains at forefront due to its long-term efficacy safety profiles....
sci-hub.se 参考文章(107)
Serghini M, Labidi A, Filali A, Ben Mustapha N, Fekih M, Boubaker J, Stem cell transplantation as rescue therapy for refractory Crohn's disease: a sytematic review. La Tunisie médicale. ,vol. 92, pp. 655- 659 ,(2014)
Edward Shelton, Jessica R. Allegretti, Betsy Stevens, Matthew Lucci, Hamed Khalili, Deanna D. Nguyen, Jenny Sauk, Cosmas Giallourakis, John Garber, Matthew J. Hamilton, Michal Tomczak, Fredrick Makrauer, Robert B. Burakoff, Jonathan Levine, Punyaganie de Silva, Sonia Friedman, Ashwin Ananthakrishnan, Joshua R. Korzenik, Vijay Yajnik, Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflammatory Bowel Diseases. ,vol. 21, pp. 2879- 2885 ,(2015) , 10.1097/MIB.0000000000000561
Ofer Ben-Bassat, Anna Iacono, Sue P Irwin, Mark S Silverberg, Gordon R Greenberg, None, Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience Gastroenterology. ,vol. 142, ,(2012) , 10.1016/S0016-5085(12)63121-7
Günther Eissner, Silvia Kirchner, Heidrun Lindner, Walter Kolch, Petra Janosch, Matthias Grell, Peter Scheurich, Reinhard Andreesen, Ernst Holler, None, Reverse Signaling Through Transmembrane TNF Confers Resistance to Lipopolysaccharide in Human Monocytes and Macrophages Journal of Immunology. ,vol. 164, pp. 6193- 6198 ,(2000) , 10.4049/JIMMUNOL.164.12.6193
T. Tang, S. R. Targan, Z.-S. Li, C. Xu, V. S. Byers, W. J. Sandborn, Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Alimentary Pharmacology & Therapeutics. ,vol. 33, pp. 194- 202 ,(2011) , 10.1111/J.1365-2036.2010.04515.X
Yao Wei, Weiming Zhu, Jianfeng Gong, Dong Guo, Lili Gu, Ning Li, Jieshou Li, Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease. Gastroenterology Research and Practice. ,vol. 2015, pp. 517597- 517597 ,(2015) , 10.1155/2015/517597
Claudio Fiocchi, Kazuhiro Kyokane, Kazuo Kusugami, Akira Imada, Kenji Ina, Gail A. West, Jugoh Itoh, Kouhei Fukushima, Alan D. Levine, Thomas S. McCormick, Takeo Yamaguchi, David G. Binion, Alessandro Musso, Eduardo G. Lapetina, Clifford A. Ottaway, George M. Dobrea, Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance Journal of Immunology. ,vol. 163, pp. 1081- 1090 ,(1999)
Orsolya Sipos, Annamária Török, Tanja Kalic, Ernő Duda, Kata Filkor, Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics Antibodies. ,vol. 4, pp. 123- 140 ,(2015) , 10.3390/ANTIB4020123
Klaudia Farkas, Mariann Rutka, Anita Bálint, Ferenc Nagy, Renáta Bor, Ágnes Milassin, Zoltán Szepes, Tamás Molnár, Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center Expert Opinion on Biological Therapy. ,vol. 15, pp. 1257- 1262 ,(2015) , 10.1517/14712598.2015.1064893
C. Steenholdt, M. Svenson, K. Bendtzen, O. Ø. Thomsen, J. Brynskov, M. A. Ainsworth, Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors’ reply Alimentary Pharmacology & Therapeutics. ,vol. 34, pp. 404- 405 ,(2011) , 10.1111/J.1365-2036.2011.04748.X